Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

26 August 2017 (15:35 - 15:50)

Organised by:

About the speaker

Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail

Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Doctor M. Farnier (Dijon, FR)

Presentation thumbnail

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Doctor G. Hovingh (Amsterdam, NL)

Presentation thumbnail

PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.

Professor P. Sever (London, GB)

Presentation thumbnail

Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)

Access the full session

Session thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

The Event

ESC Congress 2017

26 August 2017 15:35 CET

You may be interested in

Congress Presentation

Targeting the PCSK9 pathway: where do novel therapies fit in?

26 August 2022

Congress Presentation

Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study

1 September 2025

Webinar

LDL-C reduction postACS: strike early and strike strong

15 November 2021

Congress Presentation

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources